About GT20029's Efficacy and Strength Chat 3/18/2023
The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.
View this post in the Community →
Similar Community Posts Join
5 / 253 resultscommunity A concern regarding the upcoming androgen degrader drug GT20029
GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.
community PYRILUTAMIDE PHASE 3 RESULTS : No statistical significance
The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community Kintor’s KX-826 Pyrilutamide!!
KX-826 hair loss treatment completed trials with mild side effects. GT20029 may be ultimate cure, destroying androgen receptors causing baldness.
community Kintor’s GT20029 Phase 1 success
Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.
Related Research
6 / 6 results
research Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One
Adding a second method to PROTACs could improve cancer treatment.
research Topical Solutions for Androgenetic Alopecia: Evaluating Efficacy and Safety
Topical treatments for hair loss can be effective but need careful safety evaluation.
research Androgens and Androgen Receptor in the Management of Skin Diseases
Understanding how androgens and their receptors work can lead to improved treatments for skin diseases.
research The 100 Most Cited Articles in Androgenetic Alopecia: A Bibliometric Analysis
Recent research on androgenetic alopecia focuses on optimizing treatments, with promising new therapies emerging.
research What's New in Therapy for Male Androgenetic Alopecia?
research Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer
New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.